Neurology 904 - Neurology Alert - Apr 01, 2005

Target Audience:

This activity is intended for the neurologist.

Accreditation:

AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:

AHC Media designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty

Editors
Fred Plum, MD
University Professor;
Department of Neurology;
Cornell University Medical College

M. Flint Beal, MD
Professor and Chairman
Department of Neurology
Cornell University Medical College
New York, NY

Assistant Editors
Brian R. Apatoff, MD, PhD
Associate Professor of Neurology
New York Presbyterian Hospital- Cornell Campus

Steven Frucht, MD
Assistant Professor of Neurology
Movement Disorders Division
Columbia-Presbyterian Medical Center

Jeffrey Reich, MD
Assistant Professor of Neurology
New York Presbyterian Hospital
Cornell Campus

Norman R. Relkin, MD, PhD
Associate Professor
Clinical Neurology and Neuroscience
New York Presbyterian Hospital- Cornell Campus

Michael Rubin, MD
Professor of Clinical Neurology
New York-Presbyterian Hospital
Cornell Campus

Alan Z. Segal, MD
Assistant Professor
Department of Neurology
Weill-Cornell Medical College
Attending Neurologist
New York-Presbyterian Hospital

Subjects:

  • Further Evidence that Mitochondrial Dysfunction May Play a Critical Role With Migraine Pathogenesis
  • Food for Thought
  • Is it MS or Neuromyelitis Optica? A New Diagnostic Assay
  • Risk Factors for the Development of Diabetic Neuropathy
  • Acetyl Carnitine Works for Diabetic Neuropathy
  • Stroke Center Designation: Will New Administrative Hoops Translate into Improved Care?

Objectives:

  • Present current scientific data regarding diagnosis and treatment of neurologic disease, including stroke, Alzheimer?s disease, transient ischemic attack, and coma
  • Discuss the pathogenesis and treatment of pain
  • Present "basic science? lessons in brain function
  • Discuss information regarding new drugs for commonly diagnosed diseases and new uses for traditional drugs
  • Discuss nonclinical issues of importance to neurologists, such as the right to die and the physician?s legal obligation to patients with terminal illness

Financial Disclosure:

In order to reveal any potential bias in this publication, and in accordance with Accreditation Council for Continuing Medical Education guidelines, we disclose that Brian R. Apatoff, MD, PhD is on the speaker’s bureau of Biogen and Teva.

Norman R. Relkin, MD, PhD is on the speaker’s bureau of Pfizer, Eisai, and Athena Diagnostics and does research for Pfizer and Merck.

Michael Rubin, MD does research for ASTA Medica and Eli Lilly.

M. Flint Beal, MD is a consultant for Mitokor and Avicena.

Alan Z. Segal, MD is on the speaker’s bureau of Boehringer-Ingelheim.

Fred Plum, MD, Steven Frucht, MD, and Jeffrey Reich, MD, report no consultant, stockholder, speaker’s bureau, research, or other relationships related to this field of study.

Copyright 2005 AHC Media. All rights reserved.